130 related articles for article (PubMed ID: 2211960)
1. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds.
Qamar T; Gharavi AE; Levy RA; Lockshin MD
J Clin Immunol; 1990 Jul; 10(4):200-3. PubMed ID: 2211960
[TBL] [Abstract][Full Text] [Related]
2. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.
Cabral AR; Amigo MC; Cabiedes J; Alarcon-Segovia D
Am J Med; 1996 Nov; 101(5):472-81. PubMed ID: 8948270
[TBL] [Abstract][Full Text] [Related]
3. Detection of antiphospholipid autoantibody in systemic lupus erythematosus is temperature-dependent.
Cheng HM; Wang F
Immunol Invest; 1989; 18(9-10):1121-7. PubMed ID: 2613288
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex.
Sugi T; McIntyre JA
Blood; 1995 Oct; 86(8):3083-9. PubMed ID: 7579402
[TBL] [Abstract][Full Text] [Related]
5. Implications of modifying cardiolipin acyl composition by diet. 1. Cardiolipin acyl chain is an important determinant in the binding to antiphospholipid antibodies in SLE sera.
Berger A; German JB; Gershwin ME
J Autoimmun; 1992 Apr; 5(2):229-41. PubMed ID: 1627234
[TBL] [Abstract][Full Text] [Related]
6. Seronegative antiphospholipid syndrome.
Nayfe R; Uthman I; Aoun J; Saad Aldin E; Merashli M; Khamashta MA
Rheumatology (Oxford); 2013 Aug; 52(8):1358-67. PubMed ID: 23502076
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.
Cabral AR; Cabiedes J; Alarcón-Segovia D
Lupus; 2004; 13(3):182-7. PubMed ID: 15119547
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
Delgado Alves J; Kumar S; Isenberg DA
Rheumatology (Oxford); 2003 Jul; 42(7):893-9. PubMed ID: 12730551
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease.
Drouvalakis KA; Buchanan RR
J Rheumatol; 1998 Feb; 25(2):290-5. PubMed ID: 9489821
[TBL] [Abstract][Full Text] [Related]
10. The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus.
Mouritsen S; Høier-Madsen M; Wiik A; Orum O; Strandberg Pedersen N
Clin Exp Immunol; 1989 May; 76(2):178-83. PubMed ID: 2758694
[TBL] [Abstract][Full Text] [Related]
11. Heat inactivation of serum potentiates anti-cardiolipin antibody binding in ELISA.
Cheng HM; Ngeow YF; Sam CK
J Immunol Methods; 1989 Nov; 124(2):235-8. PubMed ID: 2600427
[TBL] [Abstract][Full Text] [Related]
12. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis.
Staub HL; Harris EN; Khamashta MA; Savidge G; Chahade WH; Hughes GR
Ann Rheum Dis; 1989 Feb; 48(2):166-9. PubMed ID: 2494957
[TBL] [Abstract][Full Text] [Related]
13. The BH1 idiotype defines a population of anticardiolipin antibodies closely associated with the antiphospholipid syndrome.
Mason AN; Harmer IJ; Mageed RA; Mackworth-Young CG
Lupus; 1999; 8(3):234-9. PubMed ID: 10342717
[TBL] [Abstract][Full Text] [Related]
14. Anti-phospholipid antibody isotypes in normal human sera.
Cheng HM; Wong KK
Immunol Lett; 1990 Jan; 23(3):183-6. PubMed ID: 2307490
[TBL] [Abstract][Full Text] [Related]
15. Analysis of serum binding to DNA and other ligands in systemic lupus erythematosus.
Barnes RM; Kenton P
Immunol Lett; 1985; 10(2):99-102. PubMed ID: 3897037
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis.
Alessandri C; Sorice M; Bombardieri M; Conigliaro P; Longo A; Garofalo T; Manganelli V; Conti F; Esposti MD; Valesini G
Arthritis Res Ther; 2006; 8(6):R180. PubMed ID: 17150088
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
18. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.
Petrovas C; Vlachoyiannopoulos PG; Kordossis T; Moutsopoulos HM
J Autoimmun; 1999 Nov; 13(3):347-55. PubMed ID: 10550222
[TBL] [Abstract][Full Text] [Related]
19. Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates.
Sorice M; Griggi T; Circella A; Garofalo T; d'Agostino F; Pittoni V; Pontieri GM; Lenti L; Valesini G
J Immunol Methods; 1994 Jul; 173(1):49-54. PubMed ID: 8034985
[TBL] [Abstract][Full Text] [Related]
20. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies.
Berard M; Boffa MC; Karmochkine M; Aillaud MF; Juhan-Vague I; Francès C; Cacoub P; Piette JC; Harlé JR
J Lab Clin Med; 1993 Nov; 122(5):601-5. PubMed ID: 8228579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
